Quintiles Library

Featured Podcast

The Friday Podcast: Direct-to-Patient Registries
...
Show Filters
Scientific Poster
Using simulation and data from a real-world trial we show that this effect is not trivial and complicates the interpretation of κ changes in the interpretation of reader performance, which, admittedly can change because of a multitude of...
Explore More
Fact Sheet
Selecting the right development partner is a balancing act. Do you want a local partner or one with access to extensive global resources? Broad or focused expertise? High touch or high tech? Low cost or high value? With the Quintiles Asia Pacific Emerging Biopharma Solution, you no longer have to compromise. Working on more than 60 studies for more than 45 Asia Pacific emerging biopharma customers since 2011, we’ve learned about your distinct challenges firsthand. And we’ve incorporated customer feedback to tailor a solution focused on your...
Read More
Video 02:36
By 2025, we expect that sophisticated genomics-based tools will have transformed cancer care. In this video, Phil Breitfeld, vice president and global head of the Quintiles Therapeutic Centers of Excellence, discusses the history of genomics in oncology research and how this science is leading us to new ways of treating cancer. This is the player to use for single videos on Q.com ...
Video 03:36
Immunotherapy – using small molecules and biologics that provide therapeutic benefit by focusing the capabilities of the immune system on the tumor – promises to transform cancer care, having already shown striking patient responses. In this video, Phil Breitfeld, vice president and global head of the Quintiles Therapeutic Centers of Excellence, discusses some of the latest developments in immunotherapy for oncology. This is the player to use for single videos on Q.com ...
Video 02:44
Immunotherapy – using small molecules and biologics that provide therapeutic benefit by focusing the capabilities of the immune system on the tumor – promises to transform cancer care, having already shown striking patient responses. In this video, Phil Breitfeld, vice president and global head of the Quintiles Therapeutic Centers of Excellence, explores how immunotherapies could be used in real-world settings – alone or in combination with existing therapies – to improve cancer patients’ outcomes. This is the player to use for single videos on Q.com ...
Podcast
Having just recognized International Clinical Trials Day, Jennifer Byrne from PMG Research discusses the numerous benefits of clinical trial...
Video
Discover how Quintiles' Site and Patient Network group is fostering relationships, leveraging technology, and engaging patients.    This is the player to use for single videos on Q.com...
Presentation
During this webinar, Quintiles experts Eric Faulkner, MPH, Practice Leader, Emerging Technology Value Demonstration, Access & Commercialization and Kathryn Starzyk, Senior Director of Epidemiology, discuss new opportunities for rare diseases, how generating the right evidence can help you meet increasing multi-stakeholder demands, incorporating the patient voice into your research and delivering value at every step of the research process. Authors: Eric Faulkner, MPH, Practice Leader, Emerging Technology Value Demonstration, Access & Commercialization and Kathryn Starzyk, Senior Director of...
Explore More
Press Release
RESEARCH TRIANGLE PARK, N.C. – May 20, 2015 – Quintiles CEO Tom Pike will present at the Jefferies 2015 Global Healthcare Conference on Tuesday, June 2, 2015 in New York City at the Grand Hyatt New York. The Quintiles presentation will begin at 11:30 a.m. (EDT). Investors may access a live audio webcast of the presentation on the Quintiles’ investor relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 33,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2014’s top-75...
Read More
Press Release
RESEARCH TRIANGLE PARK, NC – May 19 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the closing of an underwritten, secondary public offering of 11,855,050 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation, Temasek Life Sciences Private Limited and Dennis Gillings, CBE, and his affiliates (the “Selling Shareholders”) at a price to the public of $65.00 per share. Of the total shares sold in the offering, Quintiles repurchased 3,855,050 shares from the underwriters at a price of $64.85 per share, which is the same as the price per share paid to the Selling Shareholders by the underwriters. Quintiles did...
Read More
Media Coverage
In this article, Stella Blackburn discusses work conducted by the Innovative Medicines Initiative (IMI) and the PROTECT consortium (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium), led by the European Medicines Agency.  The study looked at whether it’s possible to collect data directly from pregnant women without the intervention of healthcare professionals. The article was published in April 2015 by The Pregnancy & Medicine Initiative, which aims to raise awareness and help address the information vacuum concerning the use of medicines and medical treatment in pregnancy. Visit...
Read More
Fact Sheet
This infographic shows how Quintiles can help lower the costs associated with the ongoing maintenance of your established products while generating additional insights into your portfolio by providing a fully integrated regulatory, safety and benefit-risk management...
Read More
Press Release
Research Triangle Park, NC, May 14, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the pricing of an underwritten, secondary public offering of 11,855,050 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation, Temasek Life Sciences Private Limited and Dennis Gillings, CBE, and his affiliates (the “Selling Shareholders”) at a price to the public of $65.00 per share. Quintiles intends to repurchase from the underwriters a number of shares having an aggregate value of approximately $250 million. Quintiles is not offering any stock in this transaction and will not receive any proceeds from the sale of the...
Read More
Press Release
Research Triangle Park, NC, May 13, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the launch of an underwritten, secondary public offering of 11,855,050 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation, Temasek Life Sciences Private Limited and Dennis Gillings, CBE, and his affiliates (the “Selling Shareholders”), of which Quintiles intends to repurchase from the underwriters a number of shares having an aggregate value of approximately $250 million. Quintiles is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Shareholders in this...
Read More
Press Release
RESEARCH TRIANGLE PARK, NC – May 12, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) (the “Company” or “Quintiles”) today announced the completion of its previously announced refinancing.  In the refinancing, the Company’s wholly-owned subsidiary, Quintiles Transnational Corp. (“Quintiles Transnational”), entered into new senior secured credit facilities totaling $1.95 billion, consisting of a $500 million revolving credit facility and $1.45 billion of term loans. In addition, Quintiles Transnational completed the offering of its $800 million principal amount of 4.875% senior unsecured notes due 2023 (the “Senior Notes”) in a private placement that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”).  Net proceeds from the...
Read More
Presentation
This 15 minute video is a response from Jeanne Hecht, Senior Vice President, Site and Patient Networks to a conversation with physician investigators at the CNS Summit. In the presentation, Jeanne acknowledges many of the burdens facing investigators participating in clinical trials, including quality issues and business needs. By applying cutting edge technology to streamline documentation, actively involving all interested parties, and cooperating with our partners and regulatory agencies, we can modernize trials and present a better image to patients. Jeanne also discusses ways we are enhancing patient awareness and participation - all to create a better investigator experience. This is the player to use for single videos on Q.com ...
Explore More
Presentation
This presentation will describe the use of Advanced Simulation Engineering (ASE) to develop and add enhancements to Quintiles Infosario® Design, a novel approach to design and plan clinical development programs and trials. ASE offers the following advantages: Rapid, iterative, design to build superior solutions Allows business, IT, and end-users to share an understanding of a software solution The ability to determine the feasibility of a function, scenario or solution without the large investment of coding, developers and infrastructure Provides a visual, validated by stakeholders, that communicates to developers what should be produced in terms of UI and functionality. Addresses perceived shortcomings in a traditional UX approach of not delivering actionable...
Explore More
Press Release
RESEARCH TRIANGLE PARK, NC – May 6, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) (the “Company” or “Quintiles”) announced today that Quintiles Transnational Corp. (“Quintiles Transnational”), its wholly owned subsidiary, has priced $800 million principal amount of 4.875% senior unsecured notes due 2023 (the “Senior Notes”) offered in a private placement that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Company intends to use the net proceeds of the offering, together with proceeds from its previously announced proposed senior secured credit facility, which is expected to increase to a total of $1.95 billion, including $1.45 billion of term loans, to refinance its existing credit facility, as well as for...
Read More